CAJ | 학술논문

目的：观察洛铂联合依托泊苷治疗初治食管小细胞癌的疗效。方法16例初治食管小细胞癌患者全部使用洛铂与依托泊苷联合化疗方案治疗。结果完全缓解（CR）5例，占31．3％，部分缓解（PR）6例，占37．5％，稳定（SD）4例，占25％，进展（PD）1例，占6．25％，总有效率（ORR）68．8％。Ⅰ～Ⅳ度不良反应发生率以疲倦最高，全部患者均有程度不等的疲倦。贫血占41．7％，白细胞下降占39．7％，血小板下降占20．9％，厌食、恶心、呕吐占29．3％，ALT、AST 升高占14．5％，除白细胞下降外均为轻至中度反应。结论洛铂是一种安全有效的第三代铂类抗肿瘤药物，患者耐受性好，临床中可尝试应用于食管小细胞癌患者。
목적：관찰락박연합의탁박감치료초치식관소세포암적료효。방법16례초치식관소세포암환자전부사용락박여의탁박감연합화료방안치료。결과완전완해（CR）5례，점31．3％，부분완해（PR）6례，점37．5％，은정（SD）4례，점25％，진전（PD）1례，점6．25％，총유효솔（ORR）68．8％。Ⅰ～Ⅳ도불량반응발생솔이피권최고，전부환자균유정도불등적피권。빈혈점41．7％，백세포하강점39．7％，혈소판하강점20．9％，염식、악심、구토점29．3％，ALT、AST 승고점14．5％，제백세포하강외균위경지중도반응。결론락박시일충안전유효적제삼대박류항종류약물，환자내수성호，림상중가상시응용우식관소세포암환자。
Objective To observe curative effect of lobaplatin plus etoposide,the new antitumor platinum drugs,on the untreated esophageal small cell of carcinoma.Methods Sixteen patients with esophageal small cell of carcinoma were treated using the lobaplatin/vp16 regimen.Results The complete response (CR) rates were 31.3%,partial response (PR)rates were 37.5%,stable disease (SD)rates were 25%,progressive disease (PD) rates were 6.25%,overall response rate (ORR)68.8%.Languor was the most common symptom in the grade -ⅠtoⅣ adverse reactions.All patients had symptoms of languor.Other related symptoms included the anaemia (41.7%), leukocytopenia (39.7%),thrombocytopenia (20.9%),anorexia,vomiting,nausea (29.3%)and increase of ALT and AST (14.5%).The toxic effect was not serious damage.Conclusion Lobaplatin is a new and safe antitumor platinum drug with a promising clinical effect,has a good tolerance in patients,and it can try to be used in the patients who have esophageal small cell of carcinoma.